KRAS and neoplasm: Since KRAS mutation is considered a main oncogenic driver in the vast majority of PCs, we evaluated if the deregulation of the PPAR pathway could be associated with a specific KRAS mutation profile: Therefore, gene expression data of 6 KRAS-WT versus 36 KRAS-mutated tumor samples from the TCGA dataset were compared.